ReviewDermatology and therapy2022
Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature Review.
Review in Dermatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of Chronic Spontaneous Urticaria on Sleep-A Systematic Review.Dermatology and therapy · 2026Pooled it
- Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.Pharmaceutics · 2026Review
- Knowledge of chronic spontaneous urticaria management among Italian general practitioners: Baseline findings from the BRIDGE study.The World Allergy Organization journal · 2026Article
- Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).Dermatology and therapy · 2026Article
- Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines.The Korean journal of internal medicine · 2026Review
- Baseline disease duration of chronic spontaneous urticaria participants in phase III clinical trials.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Article
- Challenges in Differentiating Chronic Inducible Urticaria from Chronic Spontaneous Urticaria.Journal of inflammation research · 2026Review
- Successful Treatment of Refractory Chronic Spontaneous Urticaria with Stapokibart After Omalizumab Failure: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- An Overview of Chronic Spontaneous Urticaria: Diagnosis, Management, and Treatment.Allergy, asthma & immunology research · 2025Review
- Type 2 Inflammation and Its Role in Dermatologic Diseases.International journal of dermatology · 2025Review
- Global productivity, international collaborations, and research trends in chronic spontaneous urticaria: A bibliometric overview.The journal of allergy and clinical immunology. Global · 2025Article
- Cluster Analysis of Clinical Remission and Relapse Patterns in Chronic Urticaria: Results from the PREDICT-CU Study.Dermatology and therapy · 2025Article
- Review
- Refractory chronic spontaneous urticaria with markedly elevated eosinophilia and pigmentation: diagnostic antiparasitic therapy breaks the therapeutic impasse.Postepy dermatologii i alergologii · 2025Article
- Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience.Journal of clinical medicine · 2024Article
- A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria.Dermatology and therapy · 2024Review
- CRUSEClinical and translational allergy · 2024Article
- The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years.Frontiers in allergy · 2024Article
- Evaluation of the Immune Checkpoints, TIM-3 and PD-1, as well as Anti-Inflammatory Cytokines IL-10, and TGF-β along with Diseases Activity in Chronic Spontaneous Urticaria.International journal of molecular and cellular medicine · 2024Article
- Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status.Dermatology and therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic spontaneous (previously known as idiopathic) urticaria (CSU) is a chronic skin disease with the potential for natural remission. The objectives of this targeted literature review were to identify evidence on the clinical course of CSU, including remission rates, and to estimate cumulative remission rates for different time points.
methodsElectronic databases (MEDLINE, MEDLINE-In Process, Embase, Web of Science, BIOSIS Previews and the Cochrane Library) and relevant conference proceedings were searched to identify studies involving patients with CSU aged ≥ 12 years that provide data on remission rates and disease duration. Observational studies with patient follow-ups of ≥ 1 year or review articles were included. Data extracted from five selected studies were used to run Kaplan-Meier (KM) analyses and best-fit distributions to calculate remission rates per 4-week period and weighted averages.
resultsTen publications were included in this review. The proportion of patients achieving remission within year 1 ranged from 21 to 47%, while reported remission rate estimates at year 5 were 34% and 45%. Based on calculated 4-weekly remission rates, cumulative remission estimates ranged from 9 to 38% at year 1, from 29 to 71% at year 5 and from 52 to 93% at year 20. Cumulative weighted average estimates for the proportion of patients remitting at years 1, 5 and 20 were 17%, 45% and 73%, respectively.
conclusionsPublished evidence suggests that CSU is a self-limiting condition with variable disease severity and duration, apparently dependent on multiple factors. However, data sources differed in terms of definitions of disease severity and remission, as well as in conclusions on influencing factors. Further studies and uniform definitions are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.